NKTR — Nektar Therapeutics stock price, charts and financials

QT62Nektar Therapeutics

Nektar Therapeutics (NASDAQ: NKTR) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
74.93
-1.55-2.03%
OverviewShort InterestFilings
NKTRQT62Nektar Therapeutics·NASDAQ
74.93-2.03%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
BHVN+0.31%$14.71RAPP+1.54%$46.19HRMY+1.76%$39.08SLS-5.16%$11.39PVLA-1.93%$154.72VRDN-3.29%$22.81ABCL+39.97%$9.70STOK-1.22%$32.31
Snapshot
Index-P/E-EPS (ttm)-8.42Insider Own-Shs Outstand28.69MPerf Week8.22%
Market Cap2.19BForward P/E-EPS next Y-10.77Insider Trans-0.14%Shs Float29.14MPerf Month4.88%
Enterprise Value2.21BPEG7.40EPS next Q-Inst Own-Short Float23.40%Perf Quarter-8.26%
Income-183.42MP/S39.44EPS this Y-6.30%Inst Trans-Short Ratio5.86Perf Half Y117.77%
Sales55.63MP/B3.28EPS next Y-20.31%ROA-20.71%Short Interest6.82MPerf YTD80.89%
Book/sh-P/C-EPS next 5Y-ROE-87.00%52W High106.78 -29.83%Perf Year240.67%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-17.17%52W Low21.16 254.07%Perf 3Y880.51%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-15.76% -18.50%Gross Margin99.38%Volatility3.83% 4.67%Perf 5Y-67.71%
Dividend TTM-EV/Sales39.65EPS Y/Y TTM3.00%Oper. Margin-224.88%ATR (14)3.34Perf 10Y-68.33%
Dividend Ex-Date-Quick Ratio10.21Sales Y/Y TTM-42.86%Profit Margin-284.18%RSI (14)66.60Recom2.48
Dividend Gr. 3/5Y-Current Ratio10.21EPS Q/Q44.85%SMA209.00%Beta1.17Target Price150.17
Payout0.00%Debt/Eq0.25Sales Q/Q10.00%SMA5015.19%Rel Volume0.90Prev Close76.48
Employees63LT Debt/Eq1.42EarningsAug 13SMA20020.61%Avg Volume996.42KPrice74.93
IPO DateMay 03, 1994Option/ShortYes / YesEPS/Sales Surpr.-15.02% 1.59%Net Debt/EBITDA-0.09Volume898,833Change-2.03%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-22-26InitiatedCanaccordBuy$153
May-11-26ReiteratedWedbushNeutral$95 → $80
May-08-26ReiteratedPiper SandlerOverweight$105 → $192
Apr-21-26ReiteratedWedbushNeutral$95
Apr-20-26ReiteratedHC Wainwright & Co.Buy$165 → $185
Mar-13-26ReiteratedOppenheimerOutperform$115 → $140
Feb-10-26ReiteratedBTIGBuy$151
Feb-10-26ReiteratedHC Wainwright & Co.Buy$135 → $165
Jan-26-26ReiteratedPiper SandlerOverweight$105
Dec-16-25ReiteratedOppenheimerOutperform$98 → $115
Latest News
Jul-28-26
Jul-28-2606:00PM
Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Marketsprnewswire.com
10:55AM
Does Nektar (NKTR) Have the Potential to Rally 104.06% as Wall Street Analysts Expect?zacks.com
Jul-27-26
Jul-27-2611:18AM
Nektar: Sanofi's Exit Clears A Competitor But Raises The Bar In Atopic DermatitisSeekingAlpha
Jul-26-26
Jul-26-2602:02AM
Nektar Therapeutics (NASDAQ:NKTR) Shares Gap Up – What’s Next?defenseworld.net
Jul-24-26
Jul-24-2604:15PM
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)prnewswire.com
Jul-22-26
Jul-22-2610:56AM
NKTR Up on Start of Phase III Program on Rezpeg for Atopic Dermatitiszacks.com
07:12AM
Canaccord Genuity Initiates Coverage On Nektar Therapeutics with Buy Rating, Announces Price Target of $153Benzinga
Jul-21-26
Jul-21-2607:00AM
Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitisprnewswire.com
Company

Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue565598——————
Cost of Goods Sold Incl. D&A0031——————
Gross Profit565568——————
Selling, General and Administrative Excl. Other576977——————
Research and Development123117121——————
Other Operating Expense00-25——————
Operating Income-125-131-105——————
Interest Expense292628——————
Unusual Expense
—————————
Non-Operating Income (Expense)-4-714——————
Net Income Before Taxes-159-164-119——————
Income Taxes
000——————
Consolidated Net Income-159-164-119——————
Net Income From Continuing Operations-159-164-119——————
Net Income-159-164-119——————
EPS (Recurring)-8.42-9.73-8.68——————
EPS (Basic, Before Extraordinaries)-8.42-9.73-8.68——————
EPS (Diluted)-8.42-9.73-8.68——————
EBITDA-126-137-87——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio33.4513.071.99——————
Gross Margin100.00100.0069.39——————
Operating Margin-223.21-238.18-107.14——————
Net Margin-283.93-298.18-121.43——————
Shares Outstanding251714——————
Market Capitalization1,873719195——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$114.13$84.28$54.43$24.58$-5.27● Close Price0.00M0.49M0.97M1.46M1.95MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Zalevsky JonathanChief R&D OfficerJun 30 '26Sale70.005,681397,6709,756Jul 02
ROBIN HOWARD WPresident & CEOJun 17 '26Sale61.1910,000611,88055,045Jun 18
ROBIN HOWARD WPresident & CEOJun 16 '26Sale60.3210,000603,17665,045Jun 18
Zalevsky JonathanChief R&D OfficerJun 15 '26Sale60.715,538336,21215,437Jun 17
ROBIN HOWARD WPresident & CEOMay 19 '26Sale65.5144429,08675,045May 21
Zalevsky JonathanChief R&D OfficerMay 19 '26Sale65.5119913,03620,975May 21
Zalevsky JonathanChief R&D OfficerFeb 18 '26Sale73.0018013,14021,174Feb 20
ROBIN HOWARD WPresident & CEOFeb 18 '26Sale73.0042330,87975,489Feb 20
Zalevsky JonathanChief R&D OfficerJan 20 '26Sale35.673,867137,93621,354Jan 22
Wilson Mark AndrewChief Legal OfficerNov 25 '25Sale54.2863034,19621,585Nov 25
ROBIN HOWARD WPresident & CEONov 25 '25Sale54.282,207119,79654,245Nov 25
Zalevsky JonathanChief R&D OfficerNov 25 '25Sale54.281,15762,80218,971Nov 25
ROBIN HOWARD WPresident & CEOSep 09 '25Sale46.696,666311,21449,342Sep 11
ROBIN HOWARD WPresident & CEOSep 05 '25Sale38.536,666256,85056,008Sep 08
ROBIN HOWARD WPresident & CEOSep 04 '25Sale33.705,166174,10862,674Sep 08
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.